Viridian Therapeutics (NASDAQ:VRDN) Given New $34.00 Price Target at HC Wainwright

Viridian Therapeutics (NASDAQ:VRDN) had its target price hoisted by HC Wainwright from $27.00 to $34.00 in a research note published on Thursday,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts have also weighed in on the stock. BTIG Research upped their price target on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, September 26th. Oppenheimer restated an “outperform” rating and set a $28.00 target price (down previously from $31.00) on shares of Viridian Therapeutics in a research report on Monday, August 12th. Needham & Company LLC restated a “buy” rating and set a $38.00 target price on shares of Viridian Therapeutics in a research report on Wednesday, November 13th. The Goldman Sachs Group upped their target price on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, September 12th. Finally, Wedbush reiterated an “outperform” rating and set a $42.00 price objective on shares of Viridian Therapeutics in a research report on Monday, July 29th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $36.33.

Viridian Therapeutics Stock Down 6.9 %

VRDN opened at $20.14 on Thursday. The company has a quick ratio of 15.82, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a 50 day moving average price of $22.64 and a 200-day moving average price of $17.02. Viridian Therapeutics has a twelve month low of $11.40 and a twelve month high of $27.20. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -4.67 and a beta of 1.10.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.08 million. Equities research analysts forecast that Viridian Therapeutics will post -4.01 earnings per share for the current year.

Insider Activity at Viridian Therapeutics

In other Viridian Therapeutics news, COO Thomas W. Beetham bought 5,000 shares of the stock in a transaction dated Friday, September 27th. The shares were acquired at an average cost of $23.41 per share, for a total transaction of $117,050.00. Following the completion of the transaction, the chief operating officer now owns 6,000 shares in the company, valued at approximately $140,460. The trade was a 500.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Stephen F. Mahoney acquired 21,400 shares of the stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average price of $23.33 per share, for a total transaction of $499,262.00. Following the completion of the transaction, the chief executive officer now owns 21,400 shares in the company, valued at $499,262. The trade was a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 1,626,400 shares of company stock valued at $30,616,312. 0.65% of the stock is owned by company insiders.

Institutional Trading of Viridian Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. grew its holdings in Viridian Therapeutics by 19.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after buying an additional 799 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Viridian Therapeutics by 4.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,822 shares of the company’s stock worth $505,000 after purchasing an additional 1,135 shares during the period. Arizona State Retirement System grew its holdings in shares of Viridian Therapeutics by 14.7% during the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock worth $171,000 after purchasing an additional 1,688 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Viridian Therapeutics by 17.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company’s stock worth $318,000 after purchasing an additional 2,036 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Viridian Therapeutics by 24.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock worth $156,000 after purchasing an additional 2,359 shares during the period.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.